19 July 2018
Visiongain’ has launched a new pharma report Global Vaccine Contract Manufacturing Market Report 2018-2028: Leading Countries, Technologies and Companies
The vaccine manufacturing technology and services market has experienced considerable growth over the past decade. Vaccines are a global healthcare success, currently driven by disease burden and the expanding global population. Strong growth will be seen in the therapeutic vaccines market, driven by development of vaccines for indications such as cancer. Our research suggests that demand and technological developments in this industry will drive changes in the methods and management of vaccine production. The global vaccine market will experience strong growth throughout the forecast period, as will that for outsourced vaccine manufacturing.
The lead analyst of the report commented “The transfer of vaccine technology is more difficult compared to other industries. This is the reason why the US and the EU5 have such a dominant market share of the vaccine contract manufacturing market. Vaccine manufacturing is highly technical with stringent regulatory and quality standards which have mainly kept it within regions which have the technology and regulatory framework to accommodate production.
Although off-shoring to lower costs is very popular for other industries, the vaccine contract manufacturing market in emerging markets will mainly show growth through domestic demands, at least in the first half of the forecast period, as emerging markets still grapples with international vaccine manufacturing practises and new technology platforms.”
Leading companies featured in the report include Baxter BioPharma Solutions, Boehringer Ingelheim, Catalent, Charles River Laboratories, IDT Biologika, Lonza, Meridian Life Science, Sigma Aldrich Fine Chemicals, Merck, Synco Bio Partners
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on + 44 (0) 20 7549 9987
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The market for microbiome therapeutics is expected to commence around mid-2020 with the launch of new products relating to dermatology and gastrointestinal disorders.
04 December 2019
Technological developments in the next-generation biologics market will be the result of clinical development of multiple platforms in the next-generation antibody, antibody fragment and ALP sectors.
04 December 2019
The main drivers for the growth include technological advancements such as development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.
04 December 2019
Nucleic acid separation and purification is one of modern science and technology’s most complex and critical accomplishments.